Humanigen, Inc. Overview
Pro stress-test →Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. The company develops a portfolio of proprietary immuno-oncology and immunomodulatory antibodies, focusing on LENZ, a Humaneered® anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) immunomodulatory antibody.
Strategic Profile
Pro stress-test →The company's proprietary Humaneered® monoclonal antibodies show promise in prevention and treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy, and graft versus host disease (GvHD). Pipeline products include ifabotuzumab (anti-EphA3) for solid tumors and hematologic malignancies, and lenzilumab (anti-GM-CSF) for chronic myelomonocytic leukemia, acute graft versus host disease, COVID-19 pneumonia, asthma, CAR-T treatment-related toxicities, and rheumatoid arthritis.
Competitive Landscape
Pro stress-test →Humanigen competes in the immunomodulatory antibody and CAR-T augmentation space alongside major players like Novartis (Kymriah), Gilead/Kite (Yescarta), and emerging biotech firms developing cytokine storm therapeutics and next-generation cell therapies. The company's differentiation lies in its Humaneered® platform technology and focus on reducing CAR-T-related toxicities.
Industry Context
Humanigen, Inc. operates in Immunomodulatory antibody therapeutics.
Key facts
Founded: 2015 · Headquarters: Burlingame, California, US · Employees: N/A · Revenue: $2.5M (2022) · Market cap: N/A